Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference

CRANBURY, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
May 14, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

Presented late breaking preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research...
May 05, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
April 10, 2021 13:31 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral dosingPharmacodynamic biomarkers of p53 activation developed...
April 06, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
March 10, 2021 16:31 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
March 03, 2021 16:01 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationPC14586 granted Fast Track...
February 23, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference

CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
February 16, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
November 24, 2020 17:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...